Landmark NIH Study Reveals THC-CBD Therapy Alleviates Agitation in Dementia Patients

Buzzline

A comprehensive clinical trial conducted across the United States has discovered that a specially formulated THC-CBD treatment substantially alleviates agitation among individuals with advanced dementia. The 12-week LiBBY trial involved 120 participants eligible for hospice care from 10 different medical centers, with close to 90% of those receiving treatment demonstrating notable improvement. After two weeks, 83.9% of patients treated with the cannabinoid therapy showed progress, compared to just 30.5% in the placebo cohort. Researchers highlight that the formulation evaluated is distinct from commercial cannabis offerings and advocate for larger studies to inform future dementia management strategies.

Transcript

00:00A U.S. study has found a promising new treatment for agitation in late-stage dementia.

00:05Researchers tested a medical THC-CBD formula in 120 patients across 10 U.S. medical centers.

00:12After just two weeks, patients showed significantly less agitation than those on a placebo.

00:18By 12 weeks, nearly 90% of treated patients showed overall improvement.

00:24Researchers called the results among the strongest seen in a dementia clinical trial.

00:28Side effects were similar to the placebo group, suggesting the treatment was generally well-tolerated.

00:34The medication was a carefully developed prescription formula used under medical supervision.

00:40Experts say it is not the same as cannabis products sold in stores or online.

00:45Researchers say the findings could help improve future care for people living with advanced dementia.

Category

Transcript

Comments

Recommended